ATTR-CM

Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts
Pfizer's 'entrenched' tafamidis franchise will be tough to challenge for Alnylam, BridgeBio: analysts
Fierce Pharma
Pfizer
BridgeBio
Alnylam
FDA
clinical trials
ATTR-CM
physicians
tafamidis
Flag link:
Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease
Despite FDA doubts, Alnylam wins expert backing for Onpattro expansion into rare heart disease
Fierce Pharma
Alnylam
FDA
Onpattro
ATTR-CM
Flag link:
FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting
FDA Questions Efficacy of Alnylam’s Drug in ATTR-CM Ahead of Adcomm Meeting
BioSpace
Alnylam
FDA
ATTR-CM
Onpattro
Flag link:
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
Yahoo/GlobeNewswire
Bridge Bio
clinical trials
acoramidis
ATTR
ATTR-CM
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
clinical trials
Sarepta Therapeutics
DMD
Elevidys
Bridge Bio
ATTR-CM
acoramidis
Sanofi
Merck KGaA
MS
tolebrutinib
Pfizer
obesity
danuglipron
Novo Nordisk
Ozempic
Verve Therapeutics
heterozygous familial hypercholesterolemia
Roche
lung cancer
tiragolumab
Vertex Pharmaceutical
VS-548
pain
JNJ
Bristol Myers Squibb
Flag link:
10 clinical trials to watch in the second half of 2023
10 clinical trials to watch in the second half of 2023
BioPharma Dive
FDA
clinical trials
Sarepta Therapeutics
Bridge Bio
Sanofi
Merck KGaA
Pfizer
Novo Nordisk
Verve Therapeutics
Roche
Vertex Pharmaceuticals
JNJ
Bristol Myers Squibb
ATTR-CM
Elevidys
tolebrutinib
evobrutinib
danuglipron
tiragolumab
VX-548
lazertinib
Flag link:
Why BridgeBio Pharma Stock Is Plunging Today
Why BridgeBio Pharma Stock Is Plunging Today
Motley Fool
BridgeBio
clinical trials
acoramidis
ATTR-CM
Flag link:
Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst
Alnylam's new Onpattro data raise fresh doubts in heart disease fight against Pfizer: analyst
Fierce Pharma
Alnylam
Onpattro
Pfizer
ATTR-CM
Flag link:
AstraZeneca and Neurimmune to develop investigational human monoclonal antibody NI006
AstraZeneca and Neurimmune to develop investigational human monoclonal antibody NI006
Biopharma Reporter
Alexion
AstraZeneca
Neurimmune
NI006
ATTR-CM
Flag link:
Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel
Pfizer Gains European Approval for Amyloidosis Drug Vyndaqel
Fierce Biotech
Europe
Pfizer
transthyretin amyloidosis
ATTR-CM
Vyndaqel
Flag link:
Pfizer's heart med Vyndaqel off and running thanks to diagnosis push: execs
Pfizer's heart med Vyndaqel off and running thanks to diagnosis push: execs
Fierce Pharma
Pfizer
Vyndaqel
ATTR-CM
Flag link:
Watch Out, Pfizer: This $2 Billion Biotech Is Coming for You
Watch Out, Pfizer: This $2 Billion Biotech Is Coming for You
Motley Fool
Pfizer
Vyndaqel
ATTR-CM
Eidos Therapeutics
AG10
Flag link:
Pfizer's heart drug impresses with fast US launch
Pfizer's heart drug impresses with fast US launch
Biopharma Dive
Pfizer
drug launches
Vyndaqel
ATTR-CM
Flag link: